Login to Your Account



Financings NEWS

Gemini Therapeutics Inc.'s $42.5 million series A round will "take us into the clinic with multiple programs," CEO James McLaughlin told BioWorld.

CEO Donald McCaffrey told BioWorld that Resverlogix Corp.'s unpaid loan of $68.8 million is "something we don't want, and our shareholders don't want it, and we are very pleased to have that circumstance on the way out."

Spruce Biosciences Inc. landed a $20 million series A last year but kept the financing under wraps, waiting for its only asset, SPR-001, to achieve its first clinical milestone.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: